VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager ("BiTAC(R)-TCE") program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to support manufacturing, analytical development and nonclinical studies required before clinical testing.
ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate. This partnership represents an important development milestone for VERAXA, as stable cell lines are critical for producing consistent, high-quality biologic drugs for clinical trials and eventual commercial manufacturing. The company’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. By engaging T cells more precisely against tumor cells, BiTAC(R) molecules aim to enhance efficacy while minimizing off-target effects, a common challenge in immunotherapy.
VERAXA recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. The company’s pipeline includes several BiTAC(R)-based candidates targeting various solid tumors. The advancement of the lead program into cell line development signals progress toward filing an Investigational New Drug (IND) application or Clinical Trial Application (CTA), which would allow VERAXA to initiate first-in-human studies. The company has not disclosed the specific target of its lead BiTAC(R)-TCE candidate but has indicated it focuses on a validated oncology target.
This development is significant for VERAXA as it transitions from research to preclinical development. The selection of ATUM, a contract research organization with expertise in cell line engineering, underscores the company’s commitment to leveraging external partners for specialized manufacturing processes. VERAXA’s stock (VRXA) may see increased investor interest as the program advances toward the clinic. For more information on VERAXA’s pipeline and news, visit the company’s newsroom at https://ibn.fm/VRXA.
